Newsroom

Senior industry leader brings substantial strategy, business development, and operations experience SOUTH SAN FRANCISCO, Calif. – August 22, 2023 – Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment of Andrew Yost, MBA, as the company’s chief business officer (CBO). Mr. Yost […]

NEU-723 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor First-of-its-kind companion diagnostic paired with NEU-723 will enable selection of patients likely to respond to therapy SOUTH SAN FRANCISCO, Calif. – February 7, 2023 – Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological […]

Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN’s long-standing experience in companion diagnostic development SOUTH SAN FRANCISCO, Calif. and GERMANTOWN, Md. and HILDEN, Germany, Sept. 14, 2022 /PRNewswire/ — Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological […]

Longtime clinical development leader will help advance pipeline of precision medicines for genetically defined neurological and immunological diseases, with initial focus on Parkinson’s disease SOUTH SAN FRANCISCO, Calif., April 12, 2022 – Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment […]

Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological and immunological diseases